key: cord-1020229-45eicjey authors: Sundaram, Suneha; Olson, Sean; Sharma, Paranjay; Rajendra, Shanmugarajah title: A Review of the Impact of the COVID-19 Pandemic on Colorectal Cancer Screening: Implications and Solutions date: 2021-11-19 journal: Pathogens DOI: 10.3390/pathogens10111508 sha: 39b0e87d3f029aa8c7ff01a27b7c8e05da2ed1a5 doc_id: 1020229 cord_uid: 45eicjey The COVID-19 pandemic has impacted all aspects of medical care, including cancer screening and preventative measures. Colorectal cancer screening declined significantly at the onset of the pandemic as the result of an intentional effort to conserve resources, prioritize emergencies and reduce risk of transmission. There has already been an increase in diagnosis at more advanced stages and symptomatic emergencies due to suspended screenings. As endoscopy units find their way back to pre-pandemic practices, a backlog of cases remains. The missed CRC diagnoses amongst the missed screenings carry a risk of increased morbidity and mortality which will only increase as time-to-diagnosis grows. This review discusses the impact of COVID-19 on colonoscopy screening rates, trends in stages/symptoms/circumstances at diagnosis, and economic and social impact of delayed diagnosis. Triaging and use of FITs are proposed solutions to the challenge of catching up with the large number of pandemic-driven missed CRC screenings. The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that has caused the COVID-19 pandemic is, like the previous coronaviruses and the pandemics of SARS in 2002 and Middle East Respiratory Syndrome (MERS) in 2012, a single-stranded RNA virus that originated from a zoonotic host and causes severe lower respiratory tract illness with poor mortality outcomes [1, 2] . While most patients present with respiratory symptoms, many patients also have gastrointestinal (GI) symptoms. Additionally, COVID-19 patients with and without GI symptoms have shown detectable viral loads in fecal samples [3] [4] [5] [6] [7] . Given the high transmissibility of COVID-19, the first and most important international public health task has been outbreak control, identifying the infected and employing practices to limit spread to uninfected individuals [1, 2, 8] . As a result, healthcare resources were immediately diverted to those with the greatest need, i.e., critically ill patients, and non-critical and preventative medical interventions were held across all specialties. We performed a PubMed literature search of keywords including "COVID," "colorectal cancer," "screening," "colon cancer," and "colonoscopy" to find articles that could further elucidate the impact that the pandemic has had on colorectal cancer (CRC) screenings and diagnoses numbers as well as the influence this shift may have on patients, including staging and life years lost. This paper provides a review of these findings. We included studies that published both quantitative and qualitative data from international Pathogens 2021, 10, 1508 2 of 9 populations in order to provide a robust review that captured varying patient populations. Since the onset of the COVID-19 pandemic, new systems have been put in place to gather vast data as variants arise, efficacious vaccines are available and we have gained more knowledge about COVID-19, including the risk of infection in different medical settings. It is important to make up for the backlog of cancer screenings and subsequent deficit of diagnoses in 2020 [8] [9] [10] [11] . Colorectal cancer is the third most common cancer and second leading cause of cancer-related death in the United States [12] . There have been an estimated nearly 4 million missed colorectal screening examinations due to COVID-19 [9] . Discernibly, a lack of screenings will result in late or missed cancer diagnoses for many patients. This review highlights trends in colorectal cancer screening, the potential effects on the morbidity and mortality of colorectal cancer, and proposed solutions to overcome the negatives effects of missed cancer screenings. (Figure 1 provides a summary of the key aspects covered by this review). ings and diagnoses numbers as well as the influence this shift may have on patients, including staging and life years lost. This paper provides a review of these findings. We included studies that published both quantitative and qualitative data from international populations in order to provide a robust review that captured varying patient populations. Since the onset of the COVID-19 pandemic, new systems have been put in place to gather vast data as variants arise, efficacious vaccines are available and we have gained more knowledge about COVID-19, including the risk of infection in different medical settings; . It is important to make up for the backlog of cancer screenings and subsequent deficit of diagnoses in 2020 [8] [9] [10] [11] . Colorectal cancer is the third most common cancer and second leading cause of cancer-related death in the United States [12] . There have been an estimated nearly 4 million missed colorectal screening examinations due to COVID-19 [9] . Discernibly, a lack of screenings will result in late or missed cancer diagnoses for many patients. This review highlights trends in colorectal cancer screening, the potential effects on the morbidity and mortality of colorectal cancer, and proposed solutions to overcome the negatives effects of missed cancer screenings. (Figure 1 provides a summary of the key aspects covered by this review). Early in the pandemic, multiple GI and cancer societies put forth recommendations to postpone non-urgent procedures cancer screenings to conserve healthcare resources and reduce the exposure of healthcare workers to COVID-19 [13] [14] [15] . This guidance led to a significant decline in the number of new cancers identified during the pandemic internationally. (A summary of all retrospective studies on endoscopy volume and impact on CRC detection rates is found in Early in the pandemic, multiple GI and cancer societies put forth recommendations to postpone non-urgent procedures cancer screenings to conserve healthcare resources and reduce the exposure of healthcare workers to COVID-19 [13] [14] [15] . This guidance led to a significant decline in the number of new cancers identified during the pandemic internationally. (A summary of all retrospective studies on endoscopy volume and impact on CRC detection rates is found in [17] . Multiple retrospective studies at pathology sites in Italy report decreased CRC diagnosis rates ranging from 46-62%, the largest decline compared to other cancer diagnoses over a 10-week period during the first countrywide lockdown [18, 19] . In the UK, Rutter et al. determined that from the end of March to the end of May 2020, at the first peak of COVID-19, there was a decrease of endoscopic procedures to a mere 12% of the pre-COVID volume and weekly cancer detection rates decreased by 58% over all cancers, 72% of which were missing colorectal cancer diagnoses [20] . These drastic rates of decline in endoscopy volumes correlate with a global survey of endoscopy units from 55 countries that reported an average of 85% decreased volume [21] . Morris et al. followed UK endoscopy trends through October 2020 and highlighted an important detail. There were over 60% fewer two week wait referrals for colonoscopies in high-risk patients with suspected CRC in April 2020 compared to 2019, but these numbers recovered to 2019 averages by October 2020. However, this resulted in a backlog of an estimated 3500 missed CRC diagnoses and treatments between April and October 2020 [22] . It can generally be agreed that the initial changes in procedural practices for non-urgent concerns was appropriate given the gravity of COVID-19 pandemic. However, the decrease in CRC screening endoscopies worldwide has important implications that will be devastatingly long-lasting if proper steps are not taken to address possible missed cases. Moreover, there is also consistent evidence of higher rates of cancer-related emergencies and more advanced stages at detection due to COVID-19. A single center study at a tertiary care center in the UK found that over the entire year, 2020 saw a significant increase in patients presenting with emergent large bowel obstructions and T4 cancers at diagnosis than both 2018 and 2019 [23] . Mizuno et al. describe greater rates of emergent CRC cases due to complete large bowel obstructions in a cohort of patients who underwent surgery in a cancer treatment center in Japan during the first state of emergency [24] . In Spain, a single center study in Navarra reported a significant increase in CRC diagnoses in emergency setting during the first surge of the pandemic. Fewer diagnoses were made through the screening program and more patients were diagnosed with metastatic disease at diagnosis compared to the same period in 2019 [25] . Similar trends with more advanced disease at diagnosis was observed in Brazil [26] . (Studies summarized in Table 2) With such significant reductions in screening and treatment, there is a reasonable expectation and concern that there will be an increase in CRC attributable deaths. Several models have been developed to estimate the impact of delayed screening on cancer deaths. According to a UK-based study by Maringe et al., compared to pre-pandemic figures, there will be an estimated increase of 1445-1563 additional deaths (15.2-16.6% increase) over five years as a result of the delayed diagnoses caused by the COVID-19 pandemic [27] . In a similar study, it was estimated that without implementing "catch-up" screening protocols, a 12-month disruption in screening will result in an expected increase of 1360-3968 additional deaths across the Netherlands, Australia, and Canada compared to no disruption in regular screenings [28] . In an Australian study, it was estimated that a six-month delay in colorectal cancer screening would result in an increase of over $1.2 million in healthcare costs [29] . Models and predictions are summarized in Table 2 . To address the growing backlog of cases seen at every endoscopy unit, multiple physician groups proposed adept triage pathways to identify high risk patients and prioritize alternate screening options like fecal immunochemical testing (FIT) for lower risk groups [30] . Studies of screening triage pathways are summarized in Table 1 . Most studies that implemented these new pathways were completed in the UK in an effort to reduce the number of patients on the two week wait referral list for colonoscopy. In one study, Maclean et al. offered all referred patients a FIT test. 94% of samples were returned, of which 34% were interpreted and positive and were followed by colonoscopy. The CRC diagnosis rate with this pathway was 3.7% (14 CRC of 122 colonoscopies), comparable to the pre-COVID detection rate of 3.9% [31] . Miller et al. triaged referred patients to alternate testing modalities of FIT with CT scan, FIT only, direct colonoscopy or clinical follow up. 98% of patients were triaged to the FIT+CT or FIT groups and were followed up with colonoscopy if deemed appropriate based on results. Using this pathway, they achieved a CRC detection rate of 3.1%, which is clinically similar to the CRC detection rate from 2017-2019 (3.3%) [32] . Another study utilized only clinical evaluation, CT scan or direct colonoscopy as options for triaging referred patients, which also yielded an overall similar CRC detection rate to pre-pandemic rates [33] . COVID-19 has disrupted many aspects of daily life and has transformed how almost every industry functions. The practice of medicine and how and when we deliver care to patients is no exception. COVID-19 surges and lock-downs delayed colorectal cancer screening on many patients and while endoscopy units are slowly returning to pre-pandemic practices, the missed procedures must be addressed. Without utilizing evidence based tests and re-working screening algorithms, like the triage pathways discussed here, there will be a significant economic and social impact on quality of life and life years lost. Fortunately, we have multiple tools in our armory to ensure that we continue to provide patients with appropriate preventative care. It is important that we begin to consider these options as we continue to navigate this pandemic. Triaging low versus high risk patients and using FITs (both quantitive lab-read and point-of-care) allows timely screening and focuses the work-load of endscopy units on the highest risk patients. This is especially important because resistent strains and new surges remain a real threat in prolonging this pandemic. It would be prudent to establish practice guidelines that employ multiple clinical screening methods to risk-stratify patients, diagnose colorectal cancer early and treat it appropriately as we attempt to return to on-time screening of all eligible patients and catch up with the pandemic-driven missed screenings. The goal must be to catch missed diagnoses and reach the same detection, treatment and cure rates as before the COVID-19 pandemic, with as little delay as possible. The recent emergence of the Delta and other variants of COVID-19 has undoubtedly complicated matters, which will only serve to delay this goal. The authors declare no conflict of interest. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention Lessons for COVID-19 Immunity from Other Coronavirus Infections Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis Is SARS-CoV-2 Also an Enteric Pathogen with Potential Fecal-Oral Transmission? A COVID-19 Virological and Clinical Review Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis Emergency Operations Department. Health Emergencies Programme COVID-19 Response COVID-19: Cancer Screening, Diagnosis, Post-Treatment Surveillance in Uninfected Patients during the Pandemic and Issues Related to COVID-19 Vaccination in Cancer Patients Association of Cancer Screening Deficit in the United States with the COVID-19 Pandemic Cancer Screening Tests and Cancer Diagnoses during the COVID-19 Pandemic Declines in Cancer Screening During COVID-19 Pandemic American Cancer Society Key Statistics for Colorectal Cancer COVID-19 Clinical Insights for Our Community of Gastroenterologists and Gastroenterology Care Providers Guidance for resuming GI endoscopy and practice operations after the COVID-19 pandemic American College of Surgeons COVID-19: Guidance for Triage of Non-Emergent Surgical Procedures Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic Effects of the COVID-19 Pandemic on Cancer-Related Patient Encounters Cancer diagnostic rates during the 2020 'lockdown', due to COVID-19 pandemic, compared with the 2018-2019: An audit study from cellular pathology Cancer Diagnostic Delay in Northern and Central Italy During the 2020 Lockdown Due to the Coronavirus Disease Global Impact of the COVID-19 Pandemic on Endoscopy: An International Survey of 252 Centers From 55 Countries Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: A population-based study COVID-19 and the emergency presentation of colorectal cancer. Color The number of obstructive colorectal cancers in Japan has increased during the COVID-19 pandemic: A retrospective single-center cohort study Impact of the COVID-19 pandemic during Spain's state of emergency on the diagnosis of colorectal cancer The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: A national, population-based, modelling study Impact of the COVID-19 Pandemic on Faecal Immunochemical Test-Based Colorectal Cancer Screening Programmes in Australia, Canada, and the Netherlands: A Comparative Modelling Study An Inverse Stage-Shift Model to Estimate the Excess Mortality and Health Economic Impact of Delayed Access to Cancer Services Due to the COVID-19 Pandemic Building Cancer Prevention and Control Research Capacity in Rural Appalachian Kentucky Primary Care Clinics During COVID-19: Development and Adaptation of a Multilevel Colorectal Cancer Screening Project Adoption of Faecal Immunochemical Testing for 2-Week-Wait Colorectal Patients during the COVID-19 Pandemic: An Observational Cohort Study Reporting a New Service at a Regional Centre Short-Term Outcomes of a COVID-Adapted Triage Pathway for Colorectal Cancer Detection Colorectal Cancer Referrals during the COVID-19 Pandemic-A Model for the Faster Diagnosis Standard?